(Q34167646)

31 July 2017

Diabetes, insulin treatment, and cancer risk: what is the evidence? (English)

1 reference

31 July 2017

Timothy J Lyons

2

1 reference

ORCID Public Data File 2021

author name string

Madona Azar

series ordinal

1

1 reference

31 July 2017

18 January 2010

1 reference

31 July 2017

F1000 medicine reports

1 reference

31 July 2017

2

1 reference

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

31 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Insulin glargine and malignancy: an unwarranted alarm

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Mitogenic potency of insulin glargine.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Diabetes mellitus and risk of breast cancer: a meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Glycation, carbonyl stress, EAGLEs, and the vascular complications of diabetes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Does diabetes therapy influence the risk of cancer?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Diabetes and colorectal cancer incidence in the cohort of Swedish men

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948398

Proliferative effects of insulin analogues on mammary epithelial cells

28 October 2018

1 reference

12 December 2020

Insulin glargine and cancer--an unsubstantiated allegation

1 reference

12 December 2020

Insulin glargine and cancer: another side to the story?

1 reference

12 December 2020

No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

1 reference

12 December 2020

Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells

1 reference

12 December 2020

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

1 reference

12 December 2020

Identifiers

DOI

10.3410/M2-4

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

PubMed ID

20948845